Abiopharma

Zai Lab Announces Participation in Investor Conferences in June 2025

New Form SCHEDULE 13G - Cyclacel Pharmaceuticals, Inc. Filed: 2025-08-18 AccNo: 0001493152-25-012120 Size: 6 KB

Zai Lab Complies with the HFCAA; Not Subject to Delisting*

New Form SCHEDULE 13G - Cyclacel Pharmaceuticals, Inc. Filed: 2025-08-18 AccNo: 0001493152-25-012118 Size: 6 KB

FDA approve ARTICAINE

General Announcement::CBH RAISED S$1.98 MILLION FROM PLACEMENT BACKED BY HIGH PROFILE INVESTORS TO FUEL STRATEGIC GROWTH

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab Announces Participation in Investor Conferences in March 2025

Placements::COMPLETION OF THE PROPOSED PLACEMENT CUM WARRANT ISSUE

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)

Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia

Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer

Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore